U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H28NO4.Br
Molecular Weight 438.355
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CIMETROPIUM BROMIDE

SMILES

[Br-].C[N@+]2(CC1CC1)[C@H]3C[C@@H](C[C@@H]2[C@H]4O[C@@H]34)OC(=O)[C@H](CO)C5=CC=CC=C5

InChI

InChIKey=WDURTRGFUGAJHA-GSWUYBTGSA-M
InChI=1S/C21H28NO4.BrH/c1-22(11-13-7-8-13)17-9-15(10-18(22)20-19(17)26-20)25-21(24)16(12-23)14-5-3-2-4-6-14;/h2-6,13,15-20,23H,7-12H2,1H3;1H/q+1;/p-1/t15-,16-,17-,18+,19-,20+,22?;/m1./s1

HIDE SMILES / InChI

Molecular Formula C21H27NO4
Molecular Weight 357.4434
Charge 0
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 6 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula BrH
Molecular Weight 80.912
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Cimetropium bromide (cimetropium) is a semi-synthetic belladonna alkaliod, a quaternary derivatives of scopolamine. Cimetropium was used in Italy under the name Alginor for the treatment of painful gastrointestinal conditions, such as irritant bowel syndrome or infant colics as well as in preparation for diagnostic procedures. The drug exerts its action by binding to muscarinic receptors and inhibiting their activity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ALGINOR

Approved Use

Irritable colon, spastic-painful manifestations of the gastrointestinal tract. Premedication in diagnostic and operative gastrointestinal endoscopy. In pediatrics: abdominal colic, pylori spasm, spastic gastrointestinal conditions.
Primary
ALGINOR

Approved Use

Irritable colon, spastic-painful manifestations of the gastrointestinal tract. Premedication in diagnostic and operative gastrointestinal endoscopy. In pediatrics: abdominal colic, pylori spasm, spastic gastrointestinal conditions.
Primary
ALGINOR

Approved Use

Irritable colon, spastic-painful manifestations of the gastrointestinal tract. Premedication in diagnostic and operative gastrointestinal endoscopy. In pediatrics: abdominal colic, pylori spasm, spastic gastrointestinal conditions.
Diagnostic
ALGINOR

Approved Use

Irritable colon, spastic-painful manifestations of the gastrointestinal tract. Premedication in diagnostic and operative gastrointestinal endoscopy. In pediatrics: abdominal colic, pylori spasm, spastic gastrointestinal conditions.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
23.8 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CIMETROPIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6.39 ng/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CIMETROPIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
22.68 ng × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CIMETROPIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
50 min
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CIMETROPIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
119 min
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CIMETROPIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.7 h
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CIMETROPIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
50 mg 3 times / day steady-state, oral
Studied dose
Dose: 50 mg, 3 times / day
Route: oral
Route: steady-state
Dose: 50 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Other AEs: dry mouth...
Other AEs:
dry mouth (6 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
dry mouth 6 patients
50 mg 3 times / day steady-state, oral
Studied dose
Dose: 50 mg, 3 times / day
Route: oral
Route: steady-state
Dose: 50 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Comparison between the Effectiveness of Oral Phloroglucin and Cimetropium Bromide as Premedication for Diagnostic Esophagogastroduodenoscopy: An Open-Label, Randomized, Comparative Study.
2015-01
Looking for new treatments of Infantile Colic.
2014-06-05
[Clinical phase III study of cimetropium bromide (DA3177) on the pain with upper urinary calculus: a double-blind study in comparison with scopolamine butylbromide. DA3177 Study Group].
1997-07
Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial.
1990-03
Patents

Patents

Sample Use Guides

Solution for injection: 1 vial (equivalent to 5 mg of cimetropium bromide) given intravenously or intramuscularly in the onset of painful spastic crisis. The injection can be repeated in the event of pain relapse even 3-4 times a day (spastic-painful manifestations of the gastrointestinal tract); 2 ampoules (equivalent to 10 mg of cimetropium bromide) given intravenously (preparation for instrumental investigations). Tablets: 1 tablet (equivalent to 50 mg of cimetropium bromide) 2-3 times daily in adults. Oral solution: 20 drops (equivalent to 50 mg of cimetropium bromide) 3 times per day in adults and 3-5 drops (equivalent to 1.2-2 mg of cimetropium bromide) per kg of weight 4-6 times per day in children.
Route of Administration: Other
In Vitro Use Guide
Longitudinal muscle preparations with myenteric plexus of guinea-pig ileum were treated with 0.1, 1, 10 uM cimetropium. The drug caused inhibition of contraction of the preparations, induced by exogenous ACh or electrical field stimulation. pA2 value was determined to be 7.96.
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:43:23 GMT 2025
Edited
by admin
on Wed Apr 02 09:43:23 GMT 2025
Record UNII
0C7M5WE60Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALGINOR
Preferred Name English
CIMETROPIUM BROMIDE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
(7(S)-(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.))-9-(CYCLOPROPYLMETHYL)-7-(3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-9-METHYL-3-OXA-9-AZONIATRICYCLO(3.3.1.0(SUP 2,4))NONANE BROMIDE
Common Name English
cimetropium bromide [INN]
Common Name English
CIMETROPIUM BROMIDE [MART.]
Common Name English
CIMETROPIUM BROMIDE [JAN]
Common Name English
Cimetropium bromide [WHO-DD]
Common Name English
DA-3177
Code English
N-CYCLOPROPYLMETHYLSCOPOLAMINE BROMIDE
Common Name English
3-OXA-9-AZONIATRICYCLO(3.3.1.02,4)NONANE, 9-(CYCLOPROPYLMETHYL)-7-((2S)-3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-9-METHYL-, BROMIDE (1:1), (1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.)-
Common Name English
CIMETROPIUM BROMIDE [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66880
Created by admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
WHO-VATC QA03BB05
Created by admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
WHO-ATC A03BB05
Created by admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
Code System Code Type Description
INN
5478
Created by admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
PRIMARY
NCI_THESAURUS
C90696
Created by admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
PRIMARY
CAS
51598-60-8
Created by admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
PRIMARY
SMS_ID
100000092023
Created by admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
PRIMARY
DRUG BANK
DBSALT001931
Created by admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
PRIMARY
FDA UNII
0C7M5WE60Q
Created by admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
PRIMARY
MERCK INDEX
m3553
Created by admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
PRIMARY Merck Index
WIKIPEDIA
CIMETROPIUM BROMIDE
Created by admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
PRIMARY
ChEMBL
CHEMBL2110773
Created by admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
PRIMARY
EVMPD
SUB06280MIG
Created by admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
PRIMARY
EPA CompTox
DTXSID10965919
Created by admin on Wed Apr 02 09:43:23 GMT 2025 , Edited by admin on Wed Apr 02 09:43:23 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY